Dental implants are expected to reduce the price of
Dental implants are expected to reduce the price of, the National Ordinary Session proposed to expand the collection of high-value medical supplies, the masses concerned about orthopedic supplies, drug balloon, dental implants, etc., respectively, to carry out the collection at the national and provincial levels. Dental implants into the collection, has been the trend. Dental implants are expected to reduce the price.
Dental implants are expected to reduce the price of 1January 10, Premier Li Keqiang presided over the State Council executive meeting, decided to normalize the institutionalization of drugs and high-value medical supplies centralized volume purchasing, to further reduce the burden of medicine on patients. It is worth noting that the regular meeting of the State Council proposed to expand the collection of high-value medical supplies, the masses concerned about the orthopedic supplies, drug balloon, dental implants, etc., respectively, at the national and provincial levels to carry out collection.
The current national centralized band purchasing of medicines began in 2018, initially piloted in 11 cities, and expanded to the whole country the following year. The collection of medicines, which has attracted much attention for its big drop in drug prices, has also been described as "national group purchasing", i.e., exchanging volume for market.
In addition to drugs, in recent years, high-value medical supplies set adopted into the national set of procurement, the results of 2020 is the heart stent from tens of thousands of dollars to less than 1,000 yuan. Last year's artificial joint collection, the selected products from an average of 30,000 yuan to less than 10,000 pieces, a reduction of more than 80%.
According to the expression of the regular session of the National Assembly, dental implants are also expected to enter the scope of the national and provincial collective purchasing. Dental implants is a typical "high-value medical supplies" one of the National People's Congress Li Xiaoli has described in the National People's Congress in 2021, "a county-level hospitals, the average cost of a dental implant treatment is about 6,000 yuan - 20,000 yuan ranging from the planting of a full mouth of teeth, the equivalent of buying a suite in the county. ."
In fact, the industry from last year onwards has been constantly rumored that dental implants are expected to enter the collection of sound. In the National People's Congress, Li Xiaoli has suggested that dental implants into the medical insurance, the National Health Insurance Bureau in response, said that according to the provisions of the current provinces (autonomous regions and municipalities) of glasses, denture, prosthetic eye and other appliances are not included in the basic medical insurance payment scope. However, the National Health Insurance Bureau also mentioned, encourage the conditional places according to their own level of economic development and fund affordability to develop reasonable payment standards.
And at the local level, in August last year, Ningbo City, on the "further clarification of the health insurance calendar year account to pay for dental implant program" (draft) mentioned that the proposed adjustments to the oral implant dental project overall health insurance payment standards. This was interpreted at the time, dental implants are expected to be included in the scope of the local collection.
And then, on November 17 last year, the Sichuan Provincial Pharmaceutical Bidding and Procurement Service Center issued a "notice on the part of the oral class of high-value medical consumables product information collection work". Since then, Zhejiang, Ningxia and many other places have also issued similar notices to carry out the oral medical consumables historical procurement data filling work. Such movements are again interpreted as dental implants are expected to be included in the scope of the collection.
This regular session of the National People's Congress pointed out that in recent years the reform of centralized band purchasing of medicines and high-value medical consumables has continued to promote the use of market-based mechanisms to squeeze out the inflated prices of medicines, and cumulatively save more than 260 billion yuan in health insurance and patient spending, and also promote the research and development of domestic pharmaceutical products and quality enhancement.
"The next step is to promote the centralized banded purchasing to normalize, institutionalize and speed up the expansion, so that patients can benefit." The regular state meeting briefing wrote.
Dental implants are expected to have a big price cut2According to Xinhua News Agency, on January 10, Premier Li Keqiang presided over a State Council executive meeting and decided to normalize and institutionalize centralized banded purchasing of medicines and high-value medical consumables to further reduce the burden of medicine on patients.
The regular meeting of the State Council proposed to expand the centralized purchasing of high-value medical consumables, and to carry out centralized purchasing of orthopedic consumables, drug balloons, and dental implants of concern to the masses at the national and provincial levels, respectively.
Last year, dental implants were included in some areas to explore the pilot collection, and now the national level of formalization.
In August last year, Ningbo City, on the "further clarification of the health insurance calendar year account to pay for dental implant project program" (draft) mentioned that the proposed adjustments to the oral implant dental project overall health insurance payment standards. This was interpreted at the time, dental implants are expected to be included in the scope of the local collection.
On November 17 last year, the Sichuan Provincial Pharmaceutical Bidding and Procurement Service Center issued a "notice on the collection of information on some oral high-value medical consumables products". Since then, Zhejiang, Ningxia and many other places have issued similar notices to carry out the oral medical consumables historical procurement data filling work.
Previously, the official media has focused on the phenomenon of expensive dental implants, "the world suffering to see the teeth expensive for a long time," to explore the feasibility of dental implants into the collection.
Dental implants are included in the collective purchasing, has been the trend.
In 2022, the second regular meeting of the National Assembly, dental implants into the collection of dust settled.
Implant factory prices will plummet?
How will this affect the dental industry? The first thing that can be expected is a drop in the ex-factory price of dental implants.
According to the positive view of the news reported, the "medical reform community" editor-in-chief, three medical wisdom cool (Beijing) hospital management development research institute director Wei Zi lemon in the regular session of the National People's Congress after the release of the news of the first time to express their views: dental material prices fell is inevitable.
"Once the dental implants are included in the collection and procurement, their price reduction is expected to reach 60% to 90%, different materials, different products may be different price reduction."
A significant drop in the factory price of dental implants is conducive to expanding the size of the consumer base.
From the point of view of the overall size of the market, the number of dental implants implanted in China in 2020 will be about 4.06 million, with a compound growth rate of about 30% in the past five years, but the current penetration rate of dental implants in China is still only about 29 per 10,000 people.
What is the level of this number side-by-side?
It is understood that the penetration rate of South Korea is 500 pcs/million people, Europe and the United States. Penetration rate is about 200 pills / million people, Russia and Brazil, these countries can also reach the level of 100 pills / million people. China's penetration rate of 29 pills/million people is lower than even India.
According to the 2020 China Oral Healthcare Industry Report, the total number of missing teeth in China's population has reached 2.642 billion, with 18.88 million potential dental implants, and the potential dental implant market size exceeds 200 billion yuan.
According to China's population base and the development level of aging, it is conservatively estimated that China's dental implant market has more than 10 times the growth potential.
From the current competitive landscape of the implant market, 95% of the Chinese market is made up of imported products, mainly from European, American and South Korean manufacturers, with a localization level of less than 5%.
Dental implants market localization to enhance
It is understood that China's dental implant market, South Korea's highest share of the brand Ogata, Asia's largest dental implant brand in China's market share of more than 30%; the second is also South Korea's Denton, its market share of more than 22%; market share of the third Swiss brands Stroman, with a market share of nearly 20%. The most optimistic estimate is that the market share of domestic dental implants is only about 5%.
The differences between domestic dental implants and imported brands are roughly the following: relatively low product quality, low acceptance by the dental community, little policy support, and the only advantage is the relatively favorable price.
Now that dental implants are included in the comprehensive procurement, favorable policies are conducive to smooth sales channels of domestic dental implants, bidding will become the battlefield of the major manufacturers.
The research report of Guohai Securities shows that there are dozens of domestic implant manufacturers, including West China Dental Hospital, Beijing Leiden, Weigao Jielikang, Dabo Baiduotai, Jiangsu Chuangying (by the sea biological agent), Kangtuo Medical, Ningbo Meigue Zhen, Changzhou Bakant, Shenzhen Ante, Kerunxi, etc. The larger volume of these companies is expected to be the largest implant manufacturers in the world. Among them, the larger volume of the company is expected to annual revenue of about 50 million.
The end consumer benefit is obvious
It is understood that the current end price of a dental implant is generally between 6,000-20,000 yuan, while the 2020 national per capita disposable income of 32,189 yuan, a year's income can only be planted two teeth.
Zhou Xuedong, director of the West China College of Stomatology, revealed that the hospital's most expensive implant 80,000 yuan a, if the planting of a full mouth of teeth, the equivalent of the mouth contains a high-specification version of BMW.
Although the price of dental implants medical services will not necessarily be a big drop, but the rollout of collective purchasing, will make dental implants factory price drop.
Conveyed to the end of the consumer, they "do not see the toothache, see the toothache" dilemma is expected to ease.
Dental implants are expected to reduce the price of 3
On January 10, Premier Li Keqiang presided over the State Council executive meeting, decided to normalize the institutionalization of drugs and high-value medical supplies centralized volume purchasing, to further reduce the burden of patients' medicine.
The meeting pointed out that in recent years, drugs and high-value medical supplies centralized procurement reform continues to promote the use of market-based mechanisms to effectively squeeze the medicine price is high, as of the end of the 2021 cumulative savings of health insurance and patient expenditure of 260 billion yuan, but also to promote the pharmaceutical companies will be more energy into product development, improve the quality of. The next step is to promote the centralized band purchasing normalization, institutionalization and speed up the expansion, continue to reduce the price of medicine, so that patients benefit.
The reporter noted that in January 2021, the General Office of the State Council had issued the Opinions on Promoting the Normalization and Institutionalization of Centralized Banded Purchasing of Medicines.
The opinion puts forward, to improve the market-led drug price formation mechanism, play the role of strategic purchase of health insurance fund, promote the centralized drug procurement work normalization institutionalization, improve the government organization, alliance purchasing, platform operation of the work mechanism, to guide the price of drugs to return to a reasonable level, and vigorously reduce the burden of the masses of medicines.
Continue to promote the national level of drug procurement focusing on chronic and common diseases
The State Council executive meeting pointed out that to focus on chronic and common diseases, continue to promote the national level of drug procurement, all over the country outside the national set of drugs to carry out the provincial or inter-provincial alliance procurement. By the end of this year, the national and provincial collection of drugs in each province totaled more than 350.
The editor-in-chief of the "health care reform", three medical wisdom cool (Beijing) hospital management development research institute director Wei Zilian told reporters that chronic and common diseases medication into the collection, the general population of the burden of medication to reduce the feeling will be more obvious. For example, chronic diseases basically need long-term medication, the inclusion of collective purchasing may benefit more patients, but also more will win the patient's support for the policy.
Each region of the national collection of drugs outside the provincial or inter-provincial alliance procurement, which reduces the burden of patients with the role of medicine how much?
The reporter noted that in October 2021, the State Council Leading Group on Healthcare Reform issued the "Implementation Opinions on Deepening the Deepening of the Reform of the Pharmaceutical and Healthcare System by Deeply Promoting the Experience of Sanming City, Fujian Province", which put forward the normalization and institutionalization of the state organization of the centralized banded procurement of medicines and consumables, and gradually expanding the scope of the procurement, and striving for the procurement of more than 300 generic names of medicines by the end of 2022. At the end of the "14th Five-Year Plan" period, the number of generic names of medicines purchased by national and provincial organizations in each province should be more than 500.
Wei Zi lemon said, for the National Health Insurance Bureau, at this stage, if all the health insurance catalog drugs are included in the centralized procurement, one is not necessarily have so much energy, and secondly, not every drug need to be led by the National Health Insurance Bureau.
Because of the different characteristics of different regions, such as Tibet, Qinghai to use the drug may not be commonly used in Guangdong, and Guangdong has a thalassemia, the drugs used here may not be commonly used in other provinces.
Take brucellosis as an example, only in Qinghai, Xinjiang, Inner Mongolia, Ningxia, Gansu, Shaanxi and other places with more sheep, the patient may only suffer from this disease, these areas will use the relevant drugs, but may not be used in other areas of the drug. In this case, several western provinces and regions to jointly purchase is necessary.
"In other words, it is more targeted to carry out provincial or inter-provincial alliance procurement for drugs outside the national collection." Wei Zilian said that because the Chinese market is huge, provincial or inter-provincial alliance procurement is certainly more desirable in terms of price reduction.
Orthopedic supplies, dental implants, etc., respectively, at the national and provincial levels to carry out collection
The State Council executive meeting also pointed out the need to gradually expand the coverage of high-value medical supplies collection, the masses are concerned about orthopedic supplies, drug balloon, dental implants, etc., respectively, at the national and provincial levels to carry out collection.
The reporter found that this is the first time the national level of dental implants to carry out collection.
In September 2021, the National Health Insurance Bureau has responded to the National People's Congress Li Xiaoli "dental implant material costs into the medical insurance" proposal, clearly indicated that the current provinces, autonomous regions and municipalities, glasses, dentures, prosthetic eye and other appliances are not included in the basic medical insurance payment scope.
Wei Zi lemon said, at present, China's dental implant market is very deformed, may be far more deformed than the heart stent. Data show that the price of a dental implant is about 6,000 yuan to 20,000 yuan. With the heart stent, artificial joints and other consumables have been included in the national collection, the price reduction effect is obvious, the dental implants into the medical insurance call is also increasingly high.
According to the national collection program, the current medical insurance drugs and consumables are only eligible to be included in the collection. And in the response to the proposal, the National Health Insurance Bureau did not explicitly carry out dental implant collection.
However, the National Health Insurance Bureau also pointed out in the reply, will standardize the price of oral medical services project, the split is too detailed project integration. Control of public hospitals to set their own prices for medical service items and the scale of charges. Guidance to the local implant into the platform grid range, to promote the price of each brand of implants sunshine transparent, squeeze out the water.
The industry generally believes that this means that dental implants and other high-priced consumables are expected to enter some areas of health insurance payments. And the State Council executive meeting is directly explicitly pointed out that the masses are concerned about the dental implants and other respectively at the national and provincial levels to carry out the collection of procurement.
Wei Zi lemon said, "Once the dental implants into the collection of procurement, its price reduction is expected to reach 60% to 90%, different materials, different products may be different price reduction."
In addition, this executive meeting also pointed out that to ensure the long-term stable supply of selected drugs and consumables, strengthen supervision, to ensure that the selected product price reduction does not reduce quality. Medical institutions should reasonably prioritize the use of selected products. At the same time, the implementation of the collection of health insurance fund balance retention policy, to promote the reform of the remuneration system, a reasonable increase in the income of medical personnel, better mobilization of enthusiasm.